Head-to-head evidence
ML-007C-MA vs NBI-1117570
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Muscarinic M1 and M4 receptors (agonist) · full Schizophrenia pipeline
ML-007C-MA
Developed by MapLight Therapeutics
NCT07038876 · Phase 2 · completed
This was a randomized, quadruple-masked, placebo-controlled trial with 307 participants and a clinical primary endpoint, change in PANSS total score. Because the registry does not report whether the primary endpoint was met, the available evidence supports a moderate grade rather than a stronger conclusion.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: February 2030 · NCT07459647 (registry estimate)
NBI-1117570
Developed by Neurocrine Biosciences
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2027 · NCT07288333 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ML-007C-MA's landscape · NBI-1117570's landscape